Phase I/II study of the combination of bortezomib with arsenic trioxide, ascorbic acid and high-dose melphalan for patients with multiple myeloma.

Trial Profile

Phase I/II study of the combination of bortezomib with arsenic trioxide, ascorbic acid and high-dose melphalan for patients with multiple myeloma.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 06 Aug 2012

At a glance

  • Drugs Bortezomib (Primary) ; Arsenic trioxide; Ascorbic acid; Melphalan
  • Indications Multiple myeloma
  • Focus Therapeutic Use
  • Most Recent Events

    • 01 Sep 2011 Results published in the Cancer.
    • 08 Dec 2009 Interim results presented at the 51st Annual Meeting and Exposition of the American Society of Hematology.
    • 03 Nov 2009 Actual end date (Dec 2008) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top